Penetrium: A Breakthrough in Overcoming Cold Tumors and Metastatic Cancer
/in Preclinical Research/by MaxPioglitazone: Diabetes Drug Shows Promise for Treating Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxNewsletter 18/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! As you probably know, last week was the week of AACR 2025 (American Association for Cancer Research) and AUA 2025 (American Urological Association), so we have a very packed newsletter! Enjoy the read! Stay strong and fight on! As […]
Transdermal Estradiol: A Cost-Saving, Quality-of-Life Boost for Prostate Cancer Therapy
/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- B7-H3 ADC YL201 Delivers Encouraging Results in Advanced mCRPC May 26, 2026
- Phase 1/2 Trial: Epigenetic KAT6 Inhibitor Plus Darolutamide in mCRPC May 26, 2026
- Newsletter 21/2026 May 24, 2026
- A-DREAM Trial Suggests Some Men with Metastatic Prostate Cancer May Stop Therapy Safely for a Time May 22, 2026
